Compare URBN & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URBN | RYTM |
|---|---|---|
| Founded | 1970 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.2B |
| IPO Year | 1995 | 2017 |
| Metric | URBN | RYTM |
|---|---|---|
| Price | $71.27 | $84.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $86.91 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.4M | 692.5K |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.78 | ★ 28.34 |
| EPS | ★ 5.06 | N/A |
| Revenue | ★ $6,165,376,000.00 | N/A |
| Revenue This Year | $10.67 | $55.34 |
| Revenue Next Year | $7.01 | $86.06 |
| P/E Ratio | $14.13 | ★ N/A |
| Revenue Growth | ★ 11.07 | N/A |
| 52 Week Low | $59.54 | $60.71 |
| 52 Week High | $84.35 | $122.20 |
| Indicator | URBN | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 49.98 | 42.13 |
| Support Level | $66.17 | $82.31 |
| Resistance Level | $73.74 | $90.79 |
| Average True Range (ATR) | 2.56 | 3.71 |
| MACD | 0.00 | -0.58 |
| Stochastic Oscillator | 48.27 | 1.65 |
Founded in 1970, Philadelphia-based Urban Outfitters is a multibrand apparel and home goods retailer that operates nearly 800 stores and e-commerce in the US, which accounts for about 87% of sales, as well as in other regions. Its retail nameplates are Urban Outfitters (22% of fiscal 2026 sales), Free People/Movement (26%), and Anthropologie (42%). Retail accounted for 86% of fiscal 2026 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (9% of sales). Urban Outfitters primarily markets to young adults and offers products across apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.